Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 6973-6977

  Martin, Sally K ^a   Dewar, Andrea L ^a   Farrugia, Amanda N ^a   Horvath, Noemi ^a   Gronthos, Stan ^a   To, L Bik ^a   Zannettino, Andrew C W ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

STROMAL CELL DERIVED FACTOR 1ALPHA; T 140;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE MARROW; CARCINOGENESIS; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CELL LINE, TUMOR; CHEMOKINE CXCL12; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PARAPROTEINEMIAS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845781553     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0323     Document Type: Article

References (24)

1. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
2. Munshi N, Wilson CS, Penn J, et al. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density in bone marrow biopsies. Blood 1998;92:98.
3. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-6.
4. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001;28:565-9.
5. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-6.
6. Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000;79:574-7.
7. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004;104:1159-65.
8. Di Raimondo F, Azzaro MP, Palumbo G, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800-5.
9. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α Am J Pathol 1999;154:1125-35.
10. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002;99:2703-11.
11. Gazitt Y, Akay C. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4. Stem Cells 2004;22:65-73.
12. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol Cancer Ther 2002;1:539-44.
13. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003;18:1404-18.
14. Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 2004;199:244-51.
15. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005;65:1700-9.
16. Grogan TM, Muller-Hermelink HK, Van Camp B, Harris NU, Kyle RA. Plasma cell neoplasms: mature B-cell neoplasms. In: Jaffe ES HN, Stein H, Vardiman JW, editor. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 142-56.
17. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
18. Tamamura H, Fujisawa M, Hiramatsu K, et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett 2004;569: 99-104.
19. Zhang WB, Navenot JM, Haribabu B, et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 2002;277:24515-21.
20. Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptideT140. Biochem Biophys Res Commun 1998;253:877-82.
21. Sezer O, Niemoller K, Jakob C, et al. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum β2-microglobulin levels in patients with multiple myeloma. Ann Hematol 2001; 80:598-601.
22. Mirshahi F, Pourtau J, Li H, et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 2000;99:587-94.
23. Andersen NF, Standal T, Nielsen JL, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis 7nd survival. Br J Haematol 2005;28:210-7.
24. Cibeira MT, Rozman M, Segarra M, et al. Lack of correlation between bone marrow angiogenesis estimated by microvessel density and serum angiogenic cytokines in multiple myeloma. Haematologica 2005;2005:167.